Literature DB >> 19231106

High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.

Young Seok Kim1, Jong Hoon Kim, Seung Do Ahn, Sang-Wook Lee, Seong Soo Shin, Joo-Hyun Nam, Young-Tak Kim, Yong-Man Kim, Jong-Hyeok Kim, Eun Kyung Choi.   

Abstract

PURPOSE: To determine the efficacy and toxicity of extended-field radiotherapy (RT) with concurrent platinum-based chemotherapy in patients with uterine cervical carcinoma and positive para-aortic nodes. METHODS AND MATERIALS: We retrospectively reviewed the results for 33 women with Stage IB-IVB cervical cancer. Each patient had received 59.4 Gy, including a three-dimensional conformal boost to the para-aortic lymph nodes and 41.4-50.4 Gy of external beam radiotherapy to the pelvis. Each patient also underwent six or seven applications of high-dose-rate brachytherapy (median, 5 Gy to point A at each session).
RESULTS: The median follow-up period of surviving patients was 39 months. The most common acute toxicity was hematologic, observed in 23 women. Severe acute and late gastrointestinal toxicity was observed in 3 and 4 patients, respectively. More than three-quarters of patients showed a complete response, encompassing the primary mass, metastatic pelvic, and para-aortic lymph nodes. Of the 33 women, 15 had no evidence of disease, 6 had persistent disease, 4 developed in-field failures, and 6 developed distant failures. The 5-year overall and disease-free survival rate was 47% and 42%, respectively.
CONCLUSION: Concurrent chemoradiotherapy with extended-field radiotherapy is feasible in women with uterine cervical carcinoma and positive para-aortic lymph nodes, with acceptable late morbidity and a high survival rate, although it was accompanied by substantial acute toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231106     DOI: 10.1016/j.ijrobp.2008.10.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement.

Authors:  Seok Ho Lee; Seung Heon Lee; Kyu Chan Lee; Kwang Beom Lee; Jin Woo Shin; Chan Yong Park; Sun Jin Sym; Jun-Ho Lee
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

2.  Feasibility of extended-field irradiation and intracavitary brachytherapy combined with weekly cisplatin chemosensitization for IB2-IIIB cervical cancer with positive paraaortic or high common iliac lymph nodes: a retrospective review.

Authors:  Shiho Kuji; Yasuyuki Hirashima; Satomi Komeda; Aki Tanaka; Masakazu Abe; Nobutaka Takahashi; Munetaka Takekuma; Hirofumi Asakura; Hideyuki Harada; Tetsuo Nishimura
Journal:  Int J Clin Oncol       Date:  2013-04-02       Impact factor: 3.402

3.  A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Cecelia H Boardman; William E Brady; Don S Dizon; Charles A Kunos; Kathleen N Moore; Kristine M Zanotti; Cara Matthews; Jonathan A Cosin; Carol Aghajanian; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2018-08-31       Impact factor: 5.482

4.  Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy.

Authors:  Simone Marnitz; Johanna Schram; Volker Budach; Irina Sackerer; Giuseppe Filiberto Vercellino; Jalid Sehouli; Christhardt Köhler
Journal:  Strahlenther Onkol       Date:  2014-11-21       Impact factor: 3.621

5.  Outcome of Radiation Therapy for Stage IVB Uterine Cervical Cancer With Distant Lymph Nodes Metastases; Sequential Irradiation for Distant Lymph Nodes Metastases.

Authors:  Yuki Mukai; Naho Ruiz Yokota; Madoka Sugiura; Taichi Mizushima; Risa Taniuchi; Yuichi Imai; Kotaro Hashimoto; Yuya Tabuchi; Etusko Miyagi; Masaharu Hata
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  The value of image-guided intensity-modulated radiotherapy in challenging clinical settings.

Authors:  S J Treece; M Mukesh; Y L Rimmer; S J Tudor; J C Dean; R J Benson; D L Gregory; G Horan; S J Jefferies; S G Russell; M V Williams; C B Wilson; N G Burnet
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

7.  Extended field intensity-modulated radiotherapy plus concurrent nedaplatin treatment in cervical cancer.

Authors:  Yunqin Liu; Jinming Yu; Liting Qian; Hongyan Zhang; Jun Ma
Journal:  Oncol Lett       Date:  2016-04-06       Impact factor: 2.967

8.  Efficacy of local salvage therapy for recurrent uterine cervical cancer after definitive radiotherapy.

Authors:  Shinya Hiraoka; Aya Nakajima; Noriko Kishi; Keiichi Takehana; Hideki Hanazawa; Yukinori Matsuo; Takashi Mizowaki
Journal:  Int J Clin Oncol       Date:  2021-06-24       Impact factor: 3.402

9.  Extended-field radiotherapy for locally advanced cervical cancer.

Authors:  Komsan Thamronganantasakul; Narudom Supakalin; Chumnan Kietpeerakool; Porjai Pattanittum; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26

10.  Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.

Authors:  Szu-Yuan Wu; Eng-Yen Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Hui-Chun Chen; Fu-Min Fang; Hsuan-Chih Hsu; Yu-Jie Huang
Journal:  J Radiat Res       Date:  2013-06-27       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.